- Home
- LPTX vs VGI Comparison
LPTX vs VGI Comparison
Compare LPTX & VGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- VGI
- Stock Information
- Founded
- LPTX 2011
- VGI 2012
- Country
- LPTX United States
- VGI United States
- Employees
- LPTX N/A
- VGI N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- VGI Investment Managers
- Sector
- LPTX Health Care
- VGI Finance
- Exchange
- LPTX Nasdaq
- VGI Nasdaq
- Market Cap
- LPTX 99.5M
- VGI 91.4M
- IPO Year
- LPTX N/A
- VGI N/A
- Fundamental
- Price
- LPTX $3.11
- VGI $7.77
- Analyst Decision
- LPTX Strong Buy
- VGI
- Analyst Count
- LPTX 3
- VGI 0
- Target Price
- LPTX $7.50
- VGI N/A
- AVG Volume (30 Days)
- LPTX 437.3K
- VGI 46.0K
- Earning Date
- LPTX 11-13-2024
- VGI 01-01-0001
- Dividend Yield
- LPTX N/A
- VGI 12.66%
- EPS Growth
- LPTX N/A
- VGI N/A
- EPS
- LPTX N/A
- VGI N/A
- Revenue
- LPTX N/A
- VGI N/A
- Revenue This Year
- LPTX N/A
- VGI N/A
- Revenue Next Year
- LPTX N/A
- VGI N/A
- P/E Ratio
- LPTX N/A
- VGI N/A
- Revenue Growth
- LPTX N/A
- VGI N/A
- 52 Week Low
- LPTX $1.68
- VGI $6.68
- 52 Week High
- LPTX $5.00
- VGI $7.99
- Technical
- Relative Strength Index (RSI)
- LPTX 51.79
- VGI 30.56
- Support Level
- LPTX $2.87
- VGI $8.00
- Resistance Level
- LPTX $3.12
- VGI $8.18
- Average True Range (ATR)
- LPTX 0.28
- VGI 0.08
- MACD
- LPTX 0.02
- VGI -0.03
- Stochastic Oscillator
- LPTX 49.42
- VGI 0.00
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.